Evidence map›Paper›PMID 38398452›Full record

ArticleJournal of clinical medicine2024

Down Syndrome-Basque Alzheimer Initiative (DS-BAI): Clinic-Biological Cohort.

Miren Altuna, Ainara Estanga, Adolfo Garrido, Jon Saldias, Marta Cañada, Maitane Echeverria, José Ángel Larrea, Patricia Ayo, Ainhoa Fiz, María Muñoz and 3 more

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Miren AltunaFundación CITA-Alzheimer Fundazioa, 20009 Donostia, Spain.ORCID 0000-0001-9709-5314
Ainara EstangaFundación CITA-Alzheimer Fundazioa, 20009 Donostia, Spain.
Adolfo GarridoDonostialdea Integrated Health Organisation, Clinical Biochemistry Department, Osakidetza Basque Health Service, 20014 Donostia, Spain.
Jon SaldiasFundación CITA-Alzheimer Fundazioa, 20009 Donostia, Spain.
Marta CañadaFundación CITA-Alzheimer Fundazioa, 20009 Donostia, Spain.
Maitane EcheverriaDonostialdea Integrated Health Organisation, Clinical Biochemistry Department, Osakidetza Basque Health Service, 20014 Donostia, Spain.
José Ángel LarreaDepartment of Medicine, Faculty of Health Sciences, University of Deusto, 48007 Bilbo, Spain.
Patricia AyoAtzegi, 20004 Donostia, Spain.
Ainhoa FizAtzegi, 20004 Donostia, Spain.
María MuñozFundación Goyeneche de San Sebastián, 20018 Donostia, Spain.ORCID 0009-0001-0162-8495
José Santa-InésFundación Goyeneche de San Sebastián, 20018 Donostia, Spain.
Valeria García-LandarteFEVAS Plena Inclusión Euskadi, 48009 Bilbo, Spain.
Maite García-SebastiánFundación CITA-Alzheimer Fundazioa, 20009 Donostia, Spain.ORCID 0000-0003-3480-6056
Fundacion CITA Alzheimer · ESBiogipuzkoa Health Research Institute · ESUniversidad de Deusto · ES

Funding

Diputación Foral de Gipuzkoa ("Programa de apoyo a la Red Guipuzcoana de Ciencia, Tecnología e Innovación"-2022) 2022-CIEN- 715 000097-01Diputación Foral de Gipuzkoa ("Programa de apoyo a la Red Guipuzcoana de Ciencia, Tecnología e Innovación"-2023) 2023-CIEN-000022-01Fundación Vasca de Innovación e Investigación Sanitarias / B+I+O eusko fundazioa-2023 BI022/ALZ/009La Caixa Social Foundation-2023 PV23-00113
6 · The paper itself

Abstract

backgroundDown syndrome (DS) is the most common genetically determined intellectual disability. In recent decades, it has experienced an exponential increase in life expectancy, leading to a rise in age-related diseases, including Alzheimer's disease (AD). Specific health plans for the comprehensive care of the DS community are an unmet need, which is crucial for the early and accurate diagnosis of main medical comorbidities. We present the protocol of a newly created clinical and research cohort and its feasibility in real life.

methodsThe Down Syndrome-Basque Alzheimer Initiative (DS-BAI) is a population-based, inclusive, multidisciplinary initiative for the clinical-assistance and clinical-biological research approach to aging in DS led by the CITA-Alzheimer Foundation (Donostia, Basque Country). It aims to achieve the following: (1) provide comprehensive care for adults with DS, (2) optimize access to rigorous and quality training for socio-family and healthcare references, and (3) create a valuable multimodal clinical-biological research platform.

resultsDuring the first year, 114 adults with DS joined the initiative, with 36% of them showing symptoms indicative of AD. Furthermore, adherence to training programs for healthcare professionals and families has been high, and the willingness to collaborate in basic and translational research has been encouraging.

conclusionSpecific health plans for DS and conducting clinical and translational research on the challenges of aging, including AD, are necessary and feasible.

Indexed as

agingAlzheimer’s diseasebiomarkerscognitionDown syndromeintellectual disability

Identifiers

PMID38398452
PMCPMC10889106
OpenAlexW4391948885

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.